Medipost announced Wednesday that it has acquired a domestic patent for commercializing the next-generation high-efficiency technology to culture stem cell, currently under development.

The title of the patent is “a pharmaceutical composition for preventing or treating pulmonary diseases, including mesenchymal stem cells with improved proliferation and differentiation ability.”

Medipost_{메디포스트} (CEO: Yang Yoon-sun_양윤선) has recently focused on securing high-efficiency stem cell-based technology that can improve the function and quality of stem cells, reduce production costs, and increase shelf-life.

It is a technology to prove that a pharmaceutical composition using a high-efficiency stem cell as a raw material will be useful for pulmonary tissue and pulmonary blood vessel regeneration.

Medipost named this next generation of stem cells "SMUP-Cell," and is conducting trial production according to the Good Manufacturing Practice (GMP). This is the first time the theoretically tested effect of a particular disease has been verified, the company said.

So far, Medipost has taken out patents in Korea, the U.S., and Australia for the technology to cultivate highly efficient stem cells.

Medipost also expects to develop a therapeutic drug for the intractable disease, which has been ineffective in treating the disease, since the yield is higher than that of existing stem cells by using SMUP-Cell, the company said.